Liver Assessment in Patients with Ataxia-Telangiectasia: Transient Elastography Detects Early Stages of Steatosis and Fibrosis

Background Ataxia-telangiectasia (A-T) is a rare autosomal-recessive multisystem disorder characterized by pronounced cerebellar ataxia, telangiectasia, cancer predisposition, and altered body composition. Liver diseases with steatosis, fibrosis, and hepatocellular carcinoma are frequent findings in older patients but sensitive noninvasive diagnostic tools are lacking. Objectives To determine the sensitivity of transient elastography (TE) as a screening tool for early hepatic tissue changes and serum biomarkers for liver disease. Methods Thirty-one A-T patients aged 2 to 25 years were examined prospectively from 2016–2018 by TE. In addition, we evaluated the diagnostic performance of liver biomarkers for steatosis and necroinflammatory activity (SteatoTest and ActiTest, Biopredictive, Paris) compared to TE. For calculation and comparison, patients were divided into two groups (<12, >12 years of age). Results TE revealed steatosis in 2/21 (10%) younger patients compared to 9/10 (90%) older patients. Fibrosis was present in 3/10 (30%) older patients as assessed by TE. We found a significant correlation of steatosis with SteatoTest, alpha-fetoprotein (AFP), HbA1c, and triglycerides. Liver stiffness correlated significantly with SteatoTest, ActiTest, HbA1c, and triglycerides. Conclusion Liver disease is a common finding in older A-T patients. TE is an objective measure to detect early stages of steatosis and fibrosis. SteatoTest and ActiTest are a good diagnostic assessment for steatosis and necroinflammatory activity in patients with A-T and confirmed the TE results.

[1]  R. Liberal,et al.  Splenic-hepatic elastography index is useful in differentiating between porto-sinusoidal vascular disease and cirrhosis in patients with portal hypertension. , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  Tingting Zhu,et al.  Diagnostic accuracy of transient elastography and two-dimensional shear wave elastography for staging liver fibrosis in children or adolescents: A systematic review and meta-analysis. , 2022, Current medical imaging.

[3]  R. Golfieri,et al.  A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease , 2022, The American journal of gastroenterology.

[4]  C. Sempoux,et al.  Porto-sinusoidal vascular disorder. , 2022, Journal of hepatology.

[5]  Shuangzheng Jia,et al.  Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy , 2022, Frontiers in Pediatrics.

[6]  G. Baffy,et al.  Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? , 2021, Journal of hepatology.

[7]  C. Pan,et al.  Non-Invasive Assessment of Fibrosis and Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. , 2021, Clinics and research in hepatology and gastroenterology.

[8]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[9]  R. Schubert,et al.  Diabetes in Patients With Ataxia Telangiectasia: A National Cohort Study , 2020, Frontiers in Pediatrics.

[10]  E. Herrmann,et al.  Progressive Liver Disease in Patients With Ataxia Telangiectasia , 2019, Front. Pediatr..

[11]  Y. Cho,et al.  Diagnostic Performance of Transient Elastography for Liver Fibrosis in Children: A Systematic Review and Meta-Analysis. , 2018, AJR. American journal of roentgenology.

[12]  W. Land,et al.  Origin and Consequences of Necroinflammation. , 2018, Physiological reviews.

[13]  D. Schuppan,et al.  Determinants of fibrosis progression and regression in NASH. , 2018, Journal of hepatology.

[14]  C. Kochi,et al.  Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients? , 2017, Orphanet Journal of Rare Diseases.

[15]  R. Schubert,et al.  Growth hormone treatment in patients with ataxia telangiectasia , 2017, Growth factors.

[16]  M. Kumar,et al.  Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. , 2017, Journal of hepatology.

[17]  Y. Shiloh,et al.  Ataxia-telangiectasia (A-T): An emerging dimension of premature ageing , 2017, Ageing Research Reviews.

[18]  B. Chauffert,et al.  Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[19]  T. Crawford,et al.  Ataxia telangiectasia: a review , 2016, Orphanet Journal of Rare Diseases.

[20]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[21]  A. Lahad,et al.  Liver Disease in Pediatric Patients With Ataxia Telangiectasia: A Novel Report , 2016, Journal of pediatric gastroenterology and nutrition.

[22]  A. Lahad,et al.  Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort , 2016, Pediatric Research.

[23]  B. Ben-Zeev,et al.  Ataxia telangiectasia. , 2015, Handbook of clinical neurology.

[24]  R. Schubert,et al.  Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study , 2015, Orphanet Journal of Rare Diseases.

[25]  M. Lavin,et al.  Nutritional status of patients with ataxia‐telangiectasia: A case for early and ongoing nutrition support and intervention , 2015, Journal of paediatrics and child health.

[26]  C. Kochi,et al.  Risk of Atherosclerosis in Patients with Ataxia Telangiectasia , 2015, Annals of Nutrition and Metabolism.

[27]  V. De Sanctis,et al.  Linear growth and endocrine function in children with ataxia telangiectasia , 2014, Indian journal of endocrinology and metabolism.

[28]  R. Schubert,et al.  Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia , 2014, Growth factors.

[29]  R. Wevers,et al.  Alpha-fetoprotein, a fascinating protein and biomarker in neurology. , 2014, European journal of paediatric neurology.

[30]  S. Zielen,et al.  Infections of the respiratory system in patients with ataxia–telangiectasia , 2014, Pediatric pulmonology.

[31]  Jingyuan Fu,et al.  Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? , 2014, Atherosclerosis.

[32]  J. Salmerón,et al.  Nonalcoholic Steatohepatitis in a Patient with Ataxia-Telangiectasia , 2014, Case reports in hepatology.

[33]  K. Nakao,et al.  Recent topics on α‐fetoprotein , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[34]  R. Gatti,et al.  Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. , 2013, Blood.

[35]  Grace Lai-Hung Wong,et al.  Update of liver fibrosis and steatosis with transient elastography (Fibroscan) , 2013, Gastroenterology report.

[36]  R. Weiss,et al.  The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease , 2012, Cell cycle.

[37]  M. C. Bojórquez-Ramos,et al.  Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study. , 2012, Annals of hepatology.

[38]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype , 2011 .

[39]  N. Kawada,et al.  Non-invasive diagnosis of liver fibrosis , 2011, Clinical journal of gastroenterology.

[40]  Jamey D. Young,et al.  Tracking cellular metabolomics in lipoapoptosis- and steatosis-developing liver cells. , 2011, Molecular Biosystems.

[41]  April D. Lake,et al.  Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease , 2010, Drug Metabolism and Disposition.

[42]  V. de Lédinghen,et al.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. , 2010, Ultrasound in medicine & biology.

[43]  M. Lavin,et al.  ATM Activation by Oxidative Stress , 2010, Science.

[44]  K. Cusi.  Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[45]  G. Gores,et al.  JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis* , 2009, The Journal of Biological Chemistry.

[46]  M. Lavin,et al.  Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer , 2008, Nature Reviews Molecular Cell Biology.

[47]  T. Poynard,et al.  Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. , 2008, Journal of gastrointestinal and liver diseases : JGLD.

[48]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[49]  A. Børresen-Dale,et al.  Alpha fetoprotein is increasing with age in ataxia-telangiectasia. , 2007, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[50]  Dario Conte,et al.  Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease , 2007, Gut.

[51]  Dominique Thabut,et al.  The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis , 2005, Comparative hepatology.

[52]  M. Barton,et al.  Family Members p53 and p73 Act Together in Chromatin Modification and Direct Repression of α-Fetoprotein Transcription* , 2005, Journal of Biological Chemistry.

[53]  Kyucheol Cho,et al.  Transcription Factor Interactions and Chromatin Modifications Associated with p53-Mediated, Developmental Repression of the Alpha-Fetoprotein Gene , 2005, Molecular and Cellular Biology.

[54]  M. Barton,et al.  A Direct Intersection between p53 and Transforming Growth Factor β Pathways Targets Chromatin Modification and Transcription Repression of the α-Fetoprotein Gene , 2005, Molecular and Cellular Biology.

[55]  Y. Jeng,et al.  High α‐fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: Significance of hepatitis virus infection, age, p53 and β‐catenin mutations , 2004 .

[56]  D. Thabut,et al.  Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C , 2004, Comparative hepatology.

[57]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[58]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[59]  G. Gores,et al.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. , 2003, Gastroenterology.

[60]  G. Robino,et al.  Oxidative stress-related molecules and liver fibrosis. , 2001, Journal of hepatology.

[61]  D. Schuppan,et al.  Matrix as a modulator of hepatic fibrogenesis. , 2001, Seminars in liver disease.

[62]  Müller,et al.  Anti‐oxidative capacity in patients with ataxia telangiectasia , 1999, Clinical and experimental immunology.

[63]  J. Bellanti,et al.  Ataxia telangiectasia: immunologically mediated renal and hepatic failure. , 1985, Annals of allergy.

[64]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[65]  H. Popper,et al.  Hepatic fibrosis. Correlation of biochemical and morphologic investigations. , 1970, The American journal of medicine.

[66]  E. Boder,et al.  Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. , 1958, Pediatrics.

[67]  J. Ladero,et al.  Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[68]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[69]  M. Patil,et al.  Ataxia telangiectasia with hepatocellular carcinoma. , 2009, Indian pediatrics.

[70]  M. Lavin.  Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer , 2008, Nature Reviews Molecular Cell Biology.

[71]  M. Barton,et al.  A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene. , 2005, Molecular and cellular biology.

[72]  Y. Jeng,et al.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. , 2004, International journal of cancer.

[73]  A A Bravo,et al.  Liver biopsy. , 2001, The New England journal of medicine.